CEO of Aravax Dr Pascal HickeyThe announcement of these Phase 2 study results is a key milestone for Aravax. We have delivered a strong proof of concept for our innovative disease-modifying approach to the treatment of food allergy and believe it has the potential to play an important role as a next-generation treatment option for patients. ”
Portfolio News: Positive Results for Aravax’s Novel Treatment for Peanut Allergy
Innovation Victoria-backed Aravax achieves positive results for the Phase 2 clinical trial of its peanut allergy immunotherapy.
13 November 2026
Aravax, a Melbourne-based biotechnology company backed by Innovation Victoria, has achieved positive Phase 2 clinical trial results in treating peanut allergy in children in Australia and the United States. These results are a significant milestone for the company’s flagship product, PVX108, and its novel approach to addressing food allergy.
PVX108 is a next-generation immunotherapy that uses proprietary peptides to retrain the immune system to tolerate peanut in a highly targeted way, with minimal risk of treatment-induced acute allergic reactions. It is designed to be a safe and convenient-to-use therapy that reduces the severity of allergic reactions upon accidental exposure to peanuts. In the US, Aravax has received Fast Track designation from the US Food and Drug Administration (FDA) for PVX108, underscoring the potential for this innovative immunotherapy to treat a serious condition and address an unmet medical need.

Background on the clinical trials
Aravax’s Phase 2 clinical trial of PVX108 was conducted across 14 trial sites in Australia and the US. Trial participants with peanut allergy were enrolled into two cohorts: a pilot safety cohort in adolescents aged 12-17 years (Cohort 1; 24 participants) and a primary efficacy and safety cohort in children aged 4 to 11 years (Cohort 2; 71 participants). The trial involved a randomised, double-blind, placebo-controlled treatment period to evaluate the efficacy and safety of PVX108 administered on a monthly basis. In Cohort 2, two dose levels (5 nmol, 50 nmol) were evaluated against placebo over a 12-month period (M12).
Highlights from the results among Cohort 2 at M12 include:
96% (68/71) of participants completed treatment and the M12 primary endpoint food challenge. There were no withdrawals due to study treatment.
The trial met its primary efficacy endpoint. At M12, there was a statistically significant 2.4-fold increase in maximum tolerated dose of peanut observed with 50nmol PVX108 (n=23) vs a 1.2-fold with placebo (n=24) in the intent to treat analysis set.
A statistically significant reduction in the severity of food challenge reactions was observed at M12 in the PVX108 50nmol group compared to placebo. At baseline, all participants experienced moderate or severe reactions at the dose of peanut to which they reacted (baseline reactive dose). At M12, 67% of the adverse reactions to the baseline reactive dose of the food challenge were graded zero or mild in the PVX108 group vs 35% graded zero or mild in the placebo group.
At M12, 39.4% of participants treated with PVX108 50nmol tolerated a cumulative dose of ≥ 443mg peanut protein vs 16.7% in the placebo group. A cumulative tolerated dose of 443mg peanut equates to a maximum tolerated dose level of 300mg, a reactive (eliciting) dose level of 600mg, or a cumulative reactive dose of 1043mg for the food challenge used in this study. (For reference, one peanut contains approximately 250-300mg peanut protein.)
There was a clear dose response relationship with PVX108 50nmol performing better than PVX108 5nmol across a range of endpoints.
Peanut skin prick test reactions were also significantly improved following PVX108 treatment compared to placebo.
A clear dose-dependent improvement was observed for child-reported outcomes relating to the emotional impact of living with a food allergy at M12 which reached significance in the PVX108 50nmol group compared to placebo.
PVX108 was well-tolerated: no treatment-related allergic adverse events, including anaphylaxis, or treatment-related serious adverse events were reported for either dose of PVX108. Treatment-related adverse events were only reported in 6 participants in total, 1 (4.2%) in the placebo group, 2 (8.3%) in the 5 nmol PVX108 group, and 3 (13%) in the 50 nmol PVX108 group. No treatment-related event was more than grade 2 in severity, and the most frequently reported of these was injection site reaction.
Following a six-month treatment-free period after the 12-month trial, Aravax conducted a follow-up study that showed the maintenance and even improvement in participants’ peanut tolerance at month 18 as compared to month 12, which indicates the disease-modifying potential of PVX108. Encouragingly, 87% of the final participants elected to continue in a 12-month open-label extension study, the results of which are anticipated for late 2027.
Impact for Victoria
Roughly 3% of children across Australia are impacted by peanut allergy, with some experiencing severe reactions such as anaphylaxis when exposed to peanuts. The current therapies available to them require indefinite daily dosing and an onerous set of precautions to manage risks. This combination of acute risk and complex precautions can adversely impact children’s lives, introducing complexities that trigger anxieties and impact social development.
If PVX108 continues to demonstrate strong results at clinical trials, the product could help to meaningful improve the lives of peanut allergy sufferers across the country and beyond, helping them avoid acute allergic reactions while restoring their tolerance to peanuts over time.
CEO of Innovation Victoria Rod BristowIt is gratifying to see the immense progress that Aravax has made toward treating peanut allergy by harnessing Victoria’s world-class research capabilities and innovation ecosystem support. We believe their flagship product could have a significant positive impact on children with food allergy across Australia. ”
Innovation Victoria originally invested in Aravax in the company’s $66 million Series B funding round in January 2024. Following this investment, Innovation Victoria has supported Aravax’s product development and testing activities in collaboration with some of Victoria’s leading research institutions, including the National Allergy Centre of Excellence (Melbourne), Alfred Health and Lifeblood Australia (Victorian facility).

News
Read all the latest news from Innovation Victoria.